Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 13 August 2025

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1662270

Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research

This article is a correction to:

  1. Current Paradigm and Futuristic Vision on New-onset Diabetes and Pancreatic Cancer Research

    1. Read original article
Russell MorelandRussell Moreland1Abigail ArredondoAbigail Arredondo1Anupam Dhasmana,Anupam Dhasmana1,2Swati Dhasmana,Swati Dhasmana1,2Shabia ShabirShabia Shabir3Asfia SiddiquaAsfia Siddiqua1Bonny BanerjeeBonny Banerjee4Murali M. Yallapu,Murali M. Yallapu1,2Stephen W. BehrmanStephen W. Behrman5Subhash C. Chauhan,Subhash C. Chauhan1,2Sheema Khan, Sheema Khan1,2*
  • 1Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States
  • 2South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX, United States
  • 3Department of Computer Science & Engineering, National Institute of Technology, Srinagar, India
  • 4Institute for Intelligent Systems, and Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN, United States
  • 5Department of Surgery, Baptist Memorial Medical Education, Memphis, TN, United States

A Correction on
Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research

by Moreland R, Arredondo A, Dhasmana A, Dhasmana S, Shabir S, Siddiqua A, Banerjee B, Yallapu MM, Behrman SW, Chauhan SC and Khan S (2025). Front. Pharmacol. 16:1543112. doi: 10.3389/fphar.2025.1543112

Supplemental Figure S1 was omitted. The file has now been published.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pancreatic cancer, new-onset diabetes, screening strategies, biomarker discovery, socio-economic factors

Citation: Moreland R, Arredondo A, Dhasmana A, Dhasmana S, Shabir S, Siddiqua A, Banerjee B, Yallapu MM, Behrman SW, Chauhan SC and Khan S (2025) Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Front. Pharmacol. 16:1662270. doi: 10.3389/fphar.2025.1662270

Received: 08 July 2025; Accepted: 10 July 2025;
Published: 13 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Moreland, Arredondo, Dhasmana, Dhasmana, Shabir, Siddiqua, Banerjee, Yallapu, Behrman, Chauhan and Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sheema Khan, c2hlZW1hLmtoYW5AdXRyZ3YuZWR1

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.